Anavex Life Sciences Corp. (AVXL)
1.82
-0.07
(-3.70%)
USD |
NASDAQ |
Oct 02, 16:00
1.815
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Free Cash Flow : -29.29M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -29.29M |
| March 31, 2026 | -32.66M |
| December 31, 2025 | -34.08M |
| September 30, 2025 | -39.04M |
| June 30, 2025 | -37.10M |
| March 31, 2025 | -29.81M |
| December 31, 2024 | -35.61M |
| September 30, 2024 | -30.81M |
| June 30, 2024 | -30.00M |
| March 31, 2024 | -32.48M |
| December 31, 2023 | -29.31M |
| September 30, 2023 | -27.78M |
| June 30, 2023 | -25.98M |
| March 31, 2023 | -25.38M |
| December 31, 2022 | -26.53M |
| September 30, 2022 | -24.24M |
| June 30, 2022 | -27.87M |
| March 31, 2022 | -28.34M |
| December 31, 2021 | -26.01M |
| September 30, 2021 | -30.38M |
| June 30, 2021 | -28.94M |
| March 31, 2021 | -25.49M |
| December 31, 2020 | -23.43M |
| September 30, 2020 | -21.29M |
| June 30, 2020 | -17.59M |
| Date | Value |
|---|---|
| March 31, 2020 | -21.02M |
| December 31, 2019 | -20.09M |
| September 30, 2019 | -18.58M |
| June 30, 2019 | -20.10M |
| March 31, 2019 | -14.68M |
| December 31, 2018 | -13.17M |
| September 30, 2018 | -12.58M |
| June 30, 2018 | -10.72M |
| March 31, 2018 | -11.61M |
| December 31, 2017 | -9.484M |
| September 30, 2017 | -9.017M |
| June 30, 2017 | -8.689M |
| March 31, 2017 | -7.938M |
| December 31, 2016 | -9.143M |
| September 30, 2016 | -9.237M |
| June 30, 2016 | -8.807M |
| March 31, 2016 | -8.013M |
| December 31, 2015 | -6.781M |
| September 30, 2015 | -4.227M |
| June 30, 2015 | -3.711M |
| March 31, 2015 | -3.241M |
| December 31, 2014 | -2.918M |
| September 30, 2014 | -2.662M |
| June 30, 2014 | -2.229M |
| March 31, 2014 | -1.302M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Sarepta Therapeutics, Inc. | 58.34M |
| Anixa Biosciences, Inc. | -7.376M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -9.096M |
| Free Cash Flow Per Share (Quarterly) | -0.0979 |
| Free Cash Flow to Equity (Quarterly) | -9.096M |
| Free Cash Flow to Firm (Quarterly) | -9.096M |
| Free Cash Flow Yield | -17.86% |